Drug Trial Radar · NCT04869501
Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer
Last checked: Nov 19, 2026Latest source record: Apr 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
No longer available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- I-Mab Biopharma US LimitedIndustry
- Sponsor type
- Industry
- First posted
- May 3, 2021
Design
- Study type
- Expanded access
- Who can join
- All sexes
Summary
As written by the sponsor on the registry.
This expanded access protocol was designed to provide TJ004309 in combination with atezolizumab to the remaining three patients with advanced or metastatic cancer who plan to continue with treatment.
Conditions
- Cancer
Interventions
TJ004309Drug
Antibody to CD73
AtezolizumabDrug
Humanized monoclonal antibody to PD-L1
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
HonorHealth Research Institute
Scottsdale, Arizona
Arizona Oncology Associates, P.C.
Tucson, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.